CYREN Ltd. Balance Sheet | Understand Stock

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q4 FY2017 As of Dec 31, 2017	Q4 FY2016 As of Dec 31, 2016	Q4 FY2015 As of Dec 31, 2015	Q4 FY2014 As of Dec 31, 2014
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
Trade receivables (net of allowances for credit losses of $97 and $118, respectively)
Deferred commissions
Prepaid expenses and other receivables
Current assets held for sale (Note 3)
Total current assets
LONG-TERM ASSETS:
Long-term deferred commissions
Long-term lease deposits and prepaid expenses
Operating lease right-of-use assets
Severance pay fund
Property and equipment, net
Intangible assets, net
Goodwill
Long-term assets held for sale (Note 3)
Total long-term assets
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables
Credit line
Convertible notes (related party)
Employees and payroll accruals
Accrued expenses and other liabilities ($0 and $4 attributable to related parties, respectively)
Earn-out consideration
Operating lease liabilities, current
Earn-out consideration and related costs
Operating lease liabilities
Deferred revenues
Deferred tax liability
Current liabilities held for sale (Note 3)
Total current liabilities

LONG-TERM LIABILITIES:
Deferred revenues
Earn-out consideration
Convertible notes (related party)
Convertible Debentures ($242 and $238 attributable to related parties, respectively)
Long-term operating lease liabilities
Deferred tax liability, net
Accrued severance pay
Other liabilities
Long-term liabilities held for sale (Note 3)
Total long-term liabilities

Ordinary shares nominal value ILS 0.15 par value - Authorized: 55,353,340 shares as of December 31, 2015 and 2014; Issued: 40,353,953 and 32,687,288 shares as of December 31, 2015 and 2014, respectively; Outstanding: 39,121,198 and 31,396,940 shares as of December 31, 2015 and 2014, respectively
SHAREHOLDERS’ EQUITY:
Ordinary shares nominal value ILS 3.00 par value; Authorized: 80,000,000 shares as of September 30, 2022 (Unaudited) and December 31, 2021; Issued and Outstanding: 7,999,808 and 4,532,943 shares as of September 30, 2022 (Unaudited) and December 31, 2021, respectively
Additional paid-in capital
Treasury shares at cost: 0 and 348,673 Ordinary shares as of December 31, 2019 and 2018, respectively
Accumulated other comprehensive loss
Accumulated deficit
Total shareholders’ equity

Total liabilities and shareholders’ equity

Comments